MK591 Size:Solid 10 mg MM-102 provides the first proof-of-concept

MM-102 provides the first proof-of-concept small molecule inhibitor to target the WDR5/MLL1 protein-protein interaction as a novel therapeutic approach for acute leukemia harboring MLL1 fusion proteins

InChiKey: BHMLHEQFWVQAJS-IITOGVPQSA-N

Smiles: COC([C@H](OC1N=C(C)C=C(C)N=1)C(O)=O)(C1C=CC=CC=1)C1C=CC=CC=1

Biomol Ther (Seoul)

Chemical Name: 2-aminoethane-1-thiol hydrochloride

MK591 Size:Solid 10 mg MM-102 provides the first proof-of-conceptQuiflapon, also known as MK 0591, is a potent and selective 5 Lipoxygenase activating protein (FLAP) inhibitor. MK 0591 is also a potent inhibitor of leukotriene (LT) biosynthesis in intact human and elicited rat polymorphonuclear leukocytes (PMNLs) (IC50 values 3. 1 and 6. 1 nM, respectively) and in human, squirrel monkey, and rat whole blood (IC50 values 510, 69, and 9 nM, respectively). MK 0591 has a high affinity for 5 lipoxygenase activating